Hannah England

Hannah advises a wide range of public and private companies, investors, and institutions in the life sciences industry on strategic transactions that are of critical strategic importance, with particular focus in licensing and collaboration transactions, asset acquisitions and divestitures, joint ventures, R&D financing arrangements, royalty monetizations, strategic manufacturing agreements, and co-commercialization arrangements. Hannah’s deal sheet illustrates the depth of her experience, and she has also been recognized by numerous publications and ranking organizations for her work in the field, including as the Life Sciences licensing and collaboration attorney of the year by LMG Life Sciences, as the practitioner of the year for IP transactions by Managing Intellectual Property Americas, and as a Life Sciences MVP by Law360.

Hannah’s clients include all manner of players in the life sciences industry and include global biotechnology and pharmaceutical companies such as Pfizer, Takeda, and Boehringer Ingelheim, smaller biotechnology pioneers such as Blueprint Medicines, Lian Bio, iTeos Therapeutics, Kiniksa Therapeutics, Shape Therapeutics, Sana Biotechnology, and Sarepta Therapeutics, royalty purchasers such as Royalty Pharma, academic institutions such as The Broad Institute, venture funds, private equity funds, and securities underwriters.